TIDMROQ
RNS Number : 2943E
Roquefort Therapeutics PLC
29 June 2023
29 June 2023
Roquefort Therapeutics plc
("Roquefort Therapeutics" or the "Company")
AGM Statement
Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF), the Main Market
listed biotech company focused on developing first in class
medicines in the high value and high growth oncology market ,
announces that at the Company's Annual General Meeting, to be held
at 9.00am today, Chairman Stephen West will make the following
statement:
"As announced at the time of our year end results, 2022 saw
Roquefort Therapeutics make significant progress, notably with the
successful fundraise and completion of the acquisition of Oncogeni
which pivoted the Company into a material oncology group. The
acquisition significantly increased the Company's pre-clinical
portfolio, therefore providing multiple opportunities for success.
With partnership agreements to develop the portfolio at leading
academic cancer research institutions signed, the foundations were
laid for the Company to create value through our strategy.
The excellent progress has continued into 2023 with the further
advancement of the in-house development of a platform of novel mRNA
cancer medicines and the signing of a strategic license agreement
with Randox Laboratories to utilise Midkine antibodies in medical
diagnostics, which will create significant time and cost advantages
for clinical trials.
We have made positive strides across our preclinical portfolio
in 2023 with our Midkine antibody program targeting metastatic
osteosarcoma producing encouraging in vivo pre-clinical data, which
falls under the orphan drug category and carries significant
commercial incentives. Our anti-cancer Midkine RNA oligonucleotide
program targeting Midkine expressing cancers produced >90% in
vitro efficacy in human liver and neuroblastoma cancer cells and
this program will now progress into in vivo studies which are
planned to complete before the end of this year. Safety and
efficacy has already been demonstrated in in vivo studies for the
MK cell therapy in leukemia and lymphomas, and for the siRNA
therapy in colon cancer. The MK cell therapy is progressing well in
development and the siRNA therapy is completing experiments to
finalise the mode of delivery.
Finally, we achieved positive in vitro results in our
anti-cancer mRNA therapeutic in breast and liver cancer, where the
studies demonstrated a statistically significant reduction in both
cancer growth and migration. We have further consolidated our
leadership position in the Midkine field by updating our filed
patents to protect the mRNA compositions and methods. Our Midkine
mRNA program is now progressing into in vivo studies at our
laboratory in Stratford-upon-Avon.
The Company's strategy is to discover and develop first-in-class
cancer medicines within the highly attractive oncology market
(forecast to surpass US$ 353.5 billion by 2030 at a CAGR of 8.4% in
2022-2030 [1] ). Within this field, Roquefort Therapeutics focuses
on the cancers that are resistant to current medicines including
breast, colon and liver cancer, where patient survival rates remain
poor. The Company's programs focus on the novel cancer targets
Midkine and STAT-6 both of which are associated with this poor
survival ([2]) (, [3]) . By blocking Midkine and STAT-6, the
Company has shown in in vivo studies, that both the cancer growth
rate and metastasis are reduced, which are the characteristics of
first-in-class cancer medicines.
All of our programs have met key R&D milestones on time and
within budget and the progress made across all our programs is
highly encouraging and in-keeping with our strategy. We look
forward to updating shareholders on our pre-clinical and business
development activities in due course."
For a further update on the Company's recent developments and
anticipated key milestones, Roquefort Therapeutics is giving a
presentation via the Investor Meet Company platform at 11am on
Wednesday, 5 July 2023:
https://www.investormeetcompany.com/roquefort-therapeutics-plc/register-investor
-ENDS-
Enquiries:
Roquefort Therapeutics plc
Stephen West (Chairman) / Ajan +44 (0)20 3918
Reginald (CEO) 8633
Hybridan LLP (Joint Broker)
Claire Louise Noyce
Optiva Securities Limited (Joint +44 (0)20 3764
Broker) 2341
+44 (0)20 3411
Christian Dennis 1881
Buchanan (Public Relations)
Ben Romney / Jamie Hooper / George +44 (0)20 7466
Beale 5000
LEI: 254900P4SISIWOR9RH34
About Roquefort Therapeutics
Roquefort Therapeutics (LSE:ROQ , OTCQB:ROQAF ) is a Main Market
listed biotech company developing first in class drugs in the high
value and high growth oncology segment prior to partnering or
selling to big pharma.
Since listing in March 2021, Roquefort Therapeutics has
successfully acquired Lyramid Pty Limited, a leader in the
development of medicines for a new therapeutic target, Midkine (a
human growth factor associated with cancer progression), and most
recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor
Sir Martin Evans, which has developed two families of innovative
cell and RNA oncology medicines.
Roquefort Therapeutics' portfolio consists of five fully funded,
novel patent-protected pre-clinical anti-cancer medicines. The
highly complementary profile of five best-in-class medicines
consists of:
-- Midkine antibodies with significant in vivo efficacy and toxicology studies;
-- Midkine RNA therapeutics with novel anti-cancer gene editing action;
-- Midkine mRNA therapeutics with novel anti-cancer approach;
-- STAT-6 siRNA therapeutics targeting solid tumours with significant in vivo efficacy; and
-- MK cell therapy with direct and NK-mediated anti-cancer action
For further information on Roquefort Therapeutics, please visit
www.roquefortplc.com and @RoquefortTherap on Twitter.
[1]
https://www.globenewswire.com/en/news-release/2023/01/24/2594388/0/en/Global-Cancer-Therapy-Market-to-Surpass-US-353-5-Billion-by-2030-Says-Coherent-Market-Insights-CMI.html
[2] Zhang L, Song X, Shao Y, Wu C, Jiang J. Prognostic value of
Midkine expression in patients with solid tumors: a systematic
review and meta-analysis. Oncotarget. 2018 Jan 4;9(37):24821-24829.
doi: 10.18632/oncotarget.23892. PMID: 29872508; PMCID:
PMC5973861.
[3] Wang CG, Ye YJ, Yuan J, Liu FF, Zhang H, Wang S. EZH2 and
STAT6 expression profiles are correlated with colorectal cancer
stage and prognosis. World J Gastroenterol 2010; 16(19): 2421-2427
[PMID: 20480530 DOI: 10.3748/wjg.v16.i19.2421 ]
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
AGMSEFFMAEDSEIM
(END) Dow Jones Newswires
June 29, 2023 02:00 ET (06:00 GMT)
Roquefort Therapeutics (LSE:ROQ)
Historical Stock Chart
From Jan 2025 to Feb 2025
Roquefort Therapeutics (LSE:ROQ)
Historical Stock Chart
From Feb 2024 to Feb 2025
